Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
- Govt Weighs Applying Mixed Care Scheme to Low Cost-Effective Drugs: Draft Growth Strategy
June 17, 2014
- PMDA Reviewing Osteoporosis Treatment Forteo for Risk of Shock, Anaphylaxis
June 17, 2014
- “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
- Regulatory Reform Proposal Including Expansion of Mixed Care Use Submitted to Prime Minister
June 16, 2014
- LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
- MHLW Panel OKs Draft Report on Medical Database Project, but Further Discussion Needed for Drug Makers’ Usage
June 12, 2014
- Expansion of “Mixed Care” Cited in Outline for New Growth Strategy
June 12, 2014
- MHLW to Seek Opinions on Abe’s New Mixed Care Plan from Advisory Panels
June 11, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Health Minister Still Cautious about Annual Drug Price Revision
June 11, 2014
- Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
- Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…